Gardedam Therapeutics launches crowdfunding for development of its novel Parkinson’s & Alzheimer’s therapies

Share Article

Gadedam Therapeutics (Gardedam) launched a crowdfunding campaign with the objective of raising $195,000 USD to support and advance its novel Parkinson’s and Alzheimer’s disease drug disovery efforts. The campaign is live on the Indiegogo platform at https://www.indiegogo.com/projects/novel-parkinson-s-alzheimer-s-therapies

Gardedam strategically integrates therapeutic focus, target family biophysics, drug discovery technology and expertise into an innovative pharmacological chaperone drug discovery approach, which synergizes to identify and develop small molecule candidates for clinical trials for neurodegenerative diseases. According to Dr. Gergely Tóth, CEO of Gardedam Therapeutics, ‘The funds raised through the crowdfunding campaign will support Gardedam’s preclinical drug discovery research, which target the DJ-1 protein that is linked to familial and sporadic Parkinson’s Disease and sporadic Alzheimer’s disease’.

About Gardedam Therapeutics
Gardedam (http://www.GardedamTherapeutics.com) is an early-stage pre-clinical biotechnology company focused on cutting-edge research to develop novel and curing therapies for Parkinson’s and Alzheimer’s disease.

Contact
Gergely Toth, PhD, MBA
CEO, Gardedam Therapeutics
email: pr(at)GardedamTherapeutics(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mariana Santos Silva
Gardedam Therapeutics
+44 7922099707
Email >

Gergely Toth, PhD, MBA
@GardedamTher
since: 10/2014
Follow >
Visit website